Skip Navigation

Treatment-Resistant Depression Study

Principal Investigator: Boadie Dunlop, MD

Population:  Adults aged 21-54 with treatment-resistant depression who haven’t responded to 2, 3 or 4 antidepressants in their current episode of depression and never met criteria for Bipolar Disorder, Psychotic Disorder, Dementia, Schizophrenia, and have never been exposed to Psilocybin. Treatment with Ketamine or ECT in the current episode is also exclusionary.

Summary: Patients who enroll in this 15-18-week study will participate in a psychotherapy-assisted one-time exposure to psilocybin (either 1mg, 10mg or 25 mg). Patients will be followed for 12 weeks following the psilocybin exposure. The initial screening visit is about 3 hours, the psilocybin exposure day will be 8 hours and all other visits will be between 30min and 3 hours long. Seven psychotherapy sessions will be conducted as part of the psilocybin treatment. There is the possibility an 8-month extension follow-up phase after the 18-week study. Study will provide $50 compensation per study visit.

Procedure: Physical exam, blood draws, interviews, questionnaires

Contact:
Phone (Tanja Mletzko Crowe): 404-712-5063
Email: study@emory.edu and tmletzk@emory.edu
Patients can go to:
www.emoryclinicaltrials.com
www.clinicaltrials.gov